Roles of aldosterone in vascular calcification: An update

Jingwei Gao, Kun Zhang, Jie Chen, Mong-Heng Wang, Jingfeng Wang, Pinming Liu, Hui Huang

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Both clinical and experimental studies have demonstrated that vascular calcification (VC) is a common pathology shared in many chronic diseases such as chronic kidney disease (CKD) and diabetes. It's an independent risk factor for cardiovascular events. Since the pathogenesis of VC is complicated, current therapies have limited effects on the regression of VC. Therefore, it is urgent to investigate the potential mechanisms and find new targets for the treatment of VC. Aldosterone (Aldo), a mineralocorticoid hormone, is the metabolite of renin-angiotensin-aldosterone system (RAAS) activation, which can exert genomic and non-genomic effects on the cardiovascular system. Recent data suggests that Aldo can promote VC. Here, we summarized the roles of Aldo in the process of VC and a series of findings indicated that Aldo could act as a potentially therapeutic target for treating VC.

Original languageEnglish (US)
Pages (from-to)186-193
Number of pages8
JournalEuropean Journal of Pharmacology
Volume786
DOIs
StatePublished - Jan 1 2016

Fingerprint

Vascular Calcification
Aldosterone
Mineralocorticoids
Renin-Angiotensin System
Cardiovascular System
Chronic Renal Insufficiency
Chronic Disease
Hormones
Pathology
Therapeutics

Keywords

  • Aldosterone
  • Genomic mechanisms
  • Non-genomic mechanisms
  • Vascular calcification
  • Vascular smooth muscle cells

ASJC Scopus subject areas

  • Pharmacology

Cite this

Roles of aldosterone in vascular calcification : An update. / Gao, Jingwei; Zhang, Kun; Chen, Jie; Wang, Mong-Heng; Wang, Jingfeng; Liu, Pinming; Huang, Hui.

In: European Journal of Pharmacology, Vol. 786, 01.01.2016, p. 186-193.

Research output: Contribution to journalReview article

Gao, Jingwei ; Zhang, Kun ; Chen, Jie ; Wang, Mong-Heng ; Wang, Jingfeng ; Liu, Pinming ; Huang, Hui. / Roles of aldosterone in vascular calcification : An update. In: European Journal of Pharmacology. 2016 ; Vol. 786. pp. 186-193.
@article{581f301146f04ddfa36343b11b7c85e5,
title = "Roles of aldosterone in vascular calcification: An update",
abstract = "Both clinical and experimental studies have demonstrated that vascular calcification (VC) is a common pathology shared in many chronic diseases such as chronic kidney disease (CKD) and diabetes. It's an independent risk factor for cardiovascular events. Since the pathogenesis of VC is complicated, current therapies have limited effects on the regression of VC. Therefore, it is urgent to investigate the potential mechanisms and find new targets for the treatment of VC. Aldosterone (Aldo), a mineralocorticoid hormone, is the metabolite of renin-angiotensin-aldosterone system (RAAS) activation, which can exert genomic and non-genomic effects on the cardiovascular system. Recent data suggests that Aldo can promote VC. Here, we summarized the roles of Aldo in the process of VC and a series of findings indicated that Aldo could act as a potentially therapeutic target for treating VC.",
keywords = "Aldosterone, Genomic mechanisms, Non-genomic mechanisms, Vascular calcification, Vascular smooth muscle cells",
author = "Jingwei Gao and Kun Zhang and Jie Chen and Mong-Heng Wang and Jingfeng Wang and Pinming Liu and Hui Huang",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.ejphar.2016.05.030",
language = "English (US)",
volume = "786",
pages = "186--193",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Roles of aldosterone in vascular calcification

T2 - An update

AU - Gao, Jingwei

AU - Zhang, Kun

AU - Chen, Jie

AU - Wang, Mong-Heng

AU - Wang, Jingfeng

AU - Liu, Pinming

AU - Huang, Hui

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Both clinical and experimental studies have demonstrated that vascular calcification (VC) is a common pathology shared in many chronic diseases such as chronic kidney disease (CKD) and diabetes. It's an independent risk factor for cardiovascular events. Since the pathogenesis of VC is complicated, current therapies have limited effects on the regression of VC. Therefore, it is urgent to investigate the potential mechanisms and find new targets for the treatment of VC. Aldosterone (Aldo), a mineralocorticoid hormone, is the metabolite of renin-angiotensin-aldosterone system (RAAS) activation, which can exert genomic and non-genomic effects on the cardiovascular system. Recent data suggests that Aldo can promote VC. Here, we summarized the roles of Aldo in the process of VC and a series of findings indicated that Aldo could act as a potentially therapeutic target for treating VC.

AB - Both clinical and experimental studies have demonstrated that vascular calcification (VC) is a common pathology shared in many chronic diseases such as chronic kidney disease (CKD) and diabetes. It's an independent risk factor for cardiovascular events. Since the pathogenesis of VC is complicated, current therapies have limited effects on the regression of VC. Therefore, it is urgent to investigate the potential mechanisms and find new targets for the treatment of VC. Aldosterone (Aldo), a mineralocorticoid hormone, is the metabolite of renin-angiotensin-aldosterone system (RAAS) activation, which can exert genomic and non-genomic effects on the cardiovascular system. Recent data suggests that Aldo can promote VC. Here, we summarized the roles of Aldo in the process of VC and a series of findings indicated that Aldo could act as a potentially therapeutic target for treating VC.

KW - Aldosterone

KW - Genomic mechanisms

KW - Non-genomic mechanisms

KW - Vascular calcification

KW - Vascular smooth muscle cells

UR - http://www.scopus.com/inward/record.url?scp=84974539590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974539590&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2016.05.030

DO - 10.1016/j.ejphar.2016.05.030

M3 - Review article

C2 - 27238972

AN - SCOPUS:84974539590

VL - 786

SP - 186

EP - 193

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -